A vector is the delivery vehicle that carries genetic material into a target cell — and in cell and gene therapy, vector selection is one of the earliest, highest-consequence decisions a development program makes. The vector chosen shapes manufacturing complexity, targeting precision, immunogenicity risk, payload capacity, and ultimately, which patients a therapy can treat and how durable its effect will be.
What Are the Main Categories of Vectors Used in CGT?
Viral vectors dominate current CGT development, largely because viruses have naturally evolved highly efficient mechanisms for entering cells and delivering genetic material — a capability researchers have learned to repurpose for therapeutic delivery while removing the virus’s natural disease-causing properties. Adeno-associated virus, commonly known as AAV, has become the leading vector platform for in vivo gene therapy, valued for a relatively favorable safety profile and the ability to achieve long-term, often single-administration gene expression in non-dividing cells.
Lentiviral vectors, derived from a class of retroviruses, are widely used in ex vivo applications, particularly hematopoietic stem cell gene therapy, because they integrate genetic material directly into the host cell’s genome, producing durable, heritable expression as modified cells divide. Retroviral vectors more broadly were among the earliest viral vectors used in gene therapy and remain in use for some applications, including several early CAR-T products. Non-viral delivery methods, including lipid nanoparticles, have more recently emerged as a meaningful alternative for specific applications, avoiding some of the manufacturing complexity and immunogenicity concerns associated with viral vectors entirely.
What Factors Drive Vector Selection for a Given Therapy?
Vector selection isn’t a single decision made in isolation — it’s a balance across several interacting factors, each of which can shift depending on the specific therapeutic target. Tissue tropism, a vector’s natural or engineered preference for particular cell types, has to align with where the therapeutic effect needs to occur; an AAV serotype that efficiently targets liver tissue is generally a poor choice for a therapy intended to reach the central nervous system, since different AAV serotypes have meaningfully different natural tissue preferences.
Payload capacity represents a hard physical constraint — each vector type can only carry genetic material up to a certain size, and AAV in particular has a relatively limited carrying capacity compared to some alternative vectors, which can rule it out entirely for therapies requiring delivery of larger genes. Whether durable, long-term integration into the host genome is desired, or whether transient, non-integrating expression is preferable, also shapes vector choice — integrating vectors like lentivirus provide lasting expression but carry a theoretical risk of disrupting normal gene function at the integration site, while non-integrating approaches avoid that specific risk but typically don’t sustain expression as long.
Why Does Pre-Existing Immunity Complicate Vector Selection?
A significant and often underappreciated complication in vector selection, particularly for AAV-based therapies, is pre-existing immunity. Because many AAV serotypes occur naturally and many people have been exposed to wild-type AAV at some point in their lives without ever becoming ill from it, a meaningful share of the patient population — current estimates suggest roughly 30 to 60 percent depending on the specific serotype — already carries neutralizing antibodies against that vector. For these patients, a therapy using that specific AAV serotype may be substantially less effective or entirely ineffective, since the patient’s immune system will neutralize the vector before it can deliver its therapeutic payload.
This reality has driven considerable research investment into engineering novel AAV capsid variants designed to evade pre-existing immunity, as well as into alternative vector platforms less subject to this constraint. It has also made vector-specific patient screening — testing for existing neutralizing antibodies before treatment — a standard part of clinical development and, in some cases, commercial patient selection for AAV-based therapies.
How Does Vector Choice Affect Manufacturing Complexity?
Different vector platforms carry meaningfully different manufacturing requirements, which in turn affects development timeline, cost, and the supply chain a company needs to build or access. Lentiviral and AAV vector manufacturing both require specialized cell culture and purification infrastructure considerably more complex than traditional biologics manufacturing, and capacity constraints across the contract manufacturing organizations that provide this specialized production have, at various points, created meaningful bottlenecks for the broader CGT field — with lead times for viral vector production batches sometimes extending 18 to 24 months during periods of high industry-wide demand.
This manufacturing reality means vector selection decisions made early in a therapy’s development — often before a company has fully validated its clinical approach — carry long-term strategic consequences for manufacturing partner selection, capital planning, and commercial scale-up timelines, well beyond the scientific rationale for choosing one vector platform over another.
What Should Companies Consider When Approaching Vector Selection?
Given how many interacting factors shape vector selection — tropism, payload capacity, durability requirements, immunogenicity risk, manufacturing complexity, and supply chain reliability — companies developing CGT therapies benefit from treating vector selection as a genuinely cross-functional decision rather than one made by research scientists in isolation from manufacturing, regulatory, and commercial considerations. A vector choice that’s scientifically optimal for achieving a desired therapeutic effect, but that introduces manufacturing constraints the company hasn’t planned for or pre-existing immunity exclusions that meaningfully shrink the addressable patient population, can undermine a program’s commercial viability even when the underlying science is sound.